Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-1.29 EPS, down 51.16% or $0.66 from last year’s $-0.63 per share.

At the moment 15 analysts are watching Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), 6 rate it “Buy”, 7 “Outperform”, 2 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 9 analysts have a mean sales target of 0.00 million. For the quarter ending Sep-16, 10 analysts have a mean sales target of 0.10 million whilst for the year ending Dec-16, 14 analysts have a mean target of 41.07 million.

In terms of earnings per share, 14 analysts have a -1.39 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 14 analysts have a -1.48 EPS mean target and for the quarter ending Sep-16 there are 15 estimates of -5.65 EPS.

The biggest institutional shareholders in Ultragenyx Pharmaceutical Inc. include Fidelity Management and Research Company which owns 6 million shares in the company valued at $653.47 million. Capital Research Global Investors is the second biggest holder with 5 million shares currently valued at 533.58 million whilst Wellington Management Company LLP has 4 million shares valued at 247.04 million.

Total shares held by institutions as of the most recent company filings are 37,115,997 with a reported 1,521,379 bought and 2,429,713 sold. These holdings make up 95.26% of the company’s outstanding shares.

Currently insiders hold 779,103 shares in the business which makes up 2.00% of shares. The biggest holder currently is Dr. Emil D. Kakkis,M.D. who owns 537,519 shares (1.38% of those outstanding), whilst Thomas R. Kassberg holds 70,204 (0.18% of shares outstanding) and William E. Aliski holds 58,110 (0.15% of shares outstanding).

The stock increased 1.14% or $0.71 during the last trading session, hitting $100.19. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has fallen 2.14% over the past 6 months and is downtrending.